SANUWAVE Health prelim Q3 revenue $4.7-4.9M, up 13-18% YoY

SANUWAVE Health, Inc.

2023-Q3 EPS reported -$0.06 revenue$13,404,000

Preliminary Q3 2023 revenue range $4.7M to $4.9M, representing 13-18% growth over Q3 2022.
UltraMist product line revenue increased >25% YoY and >10% sequentially vs Q2 2023.
UltraMist accounted for >90% of total revenue in the quarter.
Production constraints easing contributed to revenue growth; full Q3 results expected mid-November.
No other financial metrics (EPS, net income) disclosed; numbers remain preliminary.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SANUWAVE Health, Inc. reported third quarter ended September 30, 2023 results: revenue $4.7 million to $4.9 million.

Period: third quarter ended September 30, 2023
Revenue: $4.7 million to $4.9 million
Result: preliminary results

Exact text from the filing

99.1 Exhibit 99.1 SANUWAVE Health Announces Preliminary Revenue Results for the Third Quarter Ended September 30, 2023 SANUWAVE is pleased to announce preliminary revenues of $4.7 million to $4.9 million for the third quarter ended September 30, 2023 Results indicate 13-18% growth rate over Q3 2022 UltraMist revenues (systems and consumables) increased in excess

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

SANUWAVE Health, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-047516

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.